The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 April 2026•

1 min read

ProSomnus Receives FDA Clearance for RPMO2 Sleep Apnea Device

Key Facts

1The U.S. FDA granted Class II 510(k) clearance for ProSomnus's RPMO2 OSA Device.

2The RPMO2 is the first theragnostic device for sleep medicine, combining oral appliance therapy with physiologic monitoring.

ProSomnus Sleep Technologies has announced that it received Class II 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative RPMO2 device. The RPMO2 is recognized as the first "theragnostic" device in sleep medicine, integrating oral appliance therapy with continuous physiologic monitoring. This innovative device offers a non-CPAP alternative for patients suffering from Obstructive Sleep Apnea (OSA) by providing precision treatment alongside multi-night data collection. The regulatory approval marks a significant milestone for the company, enabling the commercialization of a technology that monitors patient compliance and efficacy in real-time. Market analysts view this clearance as a major catalyst for ProSomnus's market expansion and competitive positioning within the healthcare sector. Following the news, investor sentiment remains positive regarding the company's growth prospects in the medical device industry.